Hot Stocks Of The Day: EBAY, SOLF, SLXP, RPRX, CRIS
Monday, August 09, 2021 12:24 PM



US stocks climbed on Monday on speculation that the Federal Reserve may announce additional measures to stimulate economic growth.

Below we highlight few companies whose shares are actively trading in Monday's session. 

Shares of eBay (NASDAQ: EBAY) gained more than 2% on Monday after Skype, the Internet phone service partly owned by the online auctioneer, filed papers with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering. Last year, eBay sold 70% of the company for $1.9 billion to an investment group led by private-equity firm Silver Lake Partners.

Solarfun Power Holdings Co., Ltd. (NASDAQ: SOLF) surged more than 3% on Monday after the Chinese solar module maker announced an expansion of its marketing and customer support team based in the United States to bolster its North American presence and supplement current staff.

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) jumped more than 3% on Monday after it announced that the U.S. Food and Drug Administration has accepted for Priority Review the Company's efficacy supplement to the New Drug Application for XIFAXAN tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

Shares of Repros Therapeutics Inc. (NASDAQ: RPRX) soared more than 16% after it announced that the company has received positive written feedback from the FDA regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.

Curis Inc. (NASDAQ: CRIS) slumped more than 10% on Monday after the drug developer said that its partner Roche has informed Curis that preliminary findings from a mid-stage study of their experimental ovarian cancer drug GDC-0449 warrant additional investigation to clarify and interpret potential clinical activity of the drug candidate observed in the trial. Roche has indicated that it plans to further analyze the data, including subset analyses in the coming months. Following these analyses, it expects to make a portfolio decision regarding whether, or to what extent, they will continue development of GDC-0449 in advanced ovarian cancer.  

Disclosure: Author doesn't own any of the stocks discussed here.


 

Sponsors

Advertisement


Advertisement